FDA Fast-Tracks Review of New Alzheimer's Agitation Treatment
Axsome's AXS-05 gets FDA priority review for treating agitation in Alzheimer's patients, with decision expected by April 2026.
/ 1662 items
#XY↓
Vanda Pharmaceuticals Stock Soars on FDA Approval of Motion Sickness Drug
Vanda Pharmaceuticals shares jump 19% in premarket trading after FDA approves Nereus, the first new motion sickness treatment in 40 years.
Michael Burry Compares Molina Healthcare to Warren Buffett's Geico Investment
Big Short investor Michael Burry sees Molina Healthcare as today's Geico, calling it undervalued with strong fundamentals despite 43% stock decline in 2025.
Palisade Bio Secures Japanese Patent for PALI-2108 IBD Treatment
Palisade Bio (PALI) receives Japan patent for PALI-2108, a targeted PDE4 inhibitor for ulcerative colitis and Crohn's disease, with Phase 2 trials planned for 2026.
Ultragenyx and Mereo BioPharma: What Analysts Are Saying After Trial Setbacks
Analysts react to disappointing ORBIT and COSMIC trial results for Ultragenyx and Mereo BioPharma, highlighting risks, ratings changes, and what could come next.
Applied Digital Plans Cloud Spinoff with EKSO to Form ChronoScale - Citizens Maintains $40 Target
Citizens keeps Outperform rating on Applied Digital at $40 as company plans to spin out cloud business with EKSO Bionics, creating dedicated AI compute platform ChronoScale.